12,346 Shares in Guardant Health, Inc. (NASDAQ:GH) Bought by Entropy Technologies LP

Entropy Technologies LP acquired a new position in Guardant Health, Inc. (NASDAQ:GH - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 12,346 shares of the company's stock, valued at approximately $377,000.

Several other hedge funds also recently made changes to their positions in GH. Wellington Management Group LLP boosted its holdings in shares of Guardant Health by 188.6% in the third quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company's stock worth $232,325,000 after buying an additional 6,618,785 shares during the period. Eventide Asset Management LLC boosted its holdings in shares of Guardant Health by 2.0% in the third quarter. Eventide Asset Management LLC now owns 3,837,300 shares of the company's stock worth $88,028,000 after buying an additional 76,762 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Guardant Health by 1.1% in the third quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company's stock worth $64,754,000 after buying an additional 29,686 shares during the period. ARK Investment Management LLC boosted its holdings in shares of Guardant Health by 233.5% in the third quarter. ARK Investment Management LLC now owns 1,512,694 shares of the company's stock worth $34,701,000 after buying an additional 1,059,104 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Guardant Health by 19.4% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company's stock worth $44,732,000 after buying an additional 238,037 shares during the period. Institutional investors and hedge funds own 92.60% of the company's stock.

Insider Buying and Selling at Guardant Health

In other news, Director Musa Tariq sold 2,320 shares of Guardant Health stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $35.00, for a total value of $81,200.00. Following the transaction, the director now owns 2,676 shares of the company's stock, valued at $93,660. This trade represents a 46.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold 2,652 shares of company stock worth $93,192 over the last ninety days. 5.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have commented on GH shares. JPMorgan Chase & Co. raised their target price on shares of Guardant Health from $48.00 to $50.00 and gave the stock an "overweight" rating in a report on Thursday, November 7th. Guggenheim restated a "buy" rating on shares of Guardant Health in a report on Wednesday, January 22nd. Sanford C. Bernstein decreased their price target on shares of Guardant Health from $40.00 to $35.00 and set an "outperform" rating for the company in a report on Wednesday, October 30th. Barclays initiated coverage on shares of Guardant Health in a report on Thursday, January 23rd. They set an "overweight" rating and a $60.00 price target for the company. Finally, The Goldman Sachs Group raised their price target on shares of Guardant Health from $36.00 to $49.00 and gave the stock a "buy" rating in a report on Tuesday, January 28th. Sixteen equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $42.63.

Guardant Health Trading Up 2.4 %

NASDAQ GH traded up $1.14 during trading on Friday, reaching $48.12. The company's stock had a trading volume of 2,129,865 shares, compared to its average volume of 2,321,910. The stock has a market capitalization of $5.95 billion, a PE ratio of -11.35 and a beta of 1.32. The business has a 50-day moving average price of $39.02 and a 200-day moving average price of $31.05. Guardant Health, Inc. has a 1-year low of $15.81 and a 1-year high of $50.89.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.